Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 161)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Acetylcholine |
Approved, Investigational |
Phase 4 |
|
51-84-3 |
187 |
Synonyms:
[2-(ACETYLOXY)ETHYL]TRIMETHYLAZANIUM
2-(Acetyloxy)-N,N,N-trimethylethanaminium
2-ACETOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AZANIUM
Acetilcolina cusi
Acetyl choline ion
Acetylcholine
Acetylcholine bromide
Acetylcholine cation
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
ACETYLCHOLINE, ACH
Acetylcholinium: acetyl-choline
|
ACh
ACh|E1001|O-acetylcholine
Alcon brand OF acetylcholine chloride
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
E1001
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
2 |
|
Tocopherol |
Approved, Investigational |
Phase 4 |
|
1406-66-2 |
|
Synonyms:
Methyltocols
tocoferol
tocoferoles
|
|
|
3 |
|
Tamoxifen |
Approved |
Phase 4 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Î’-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
4 |
|
Trastuzumab |
Approved, Investigational |
Phase 4 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
5 |
|
Valsartan |
Approved, Investigational |
Phase 4 |
|
137862-53-4 |
60846 |
Synonyms:
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
CGP-48933
CGP-48933|Diovan®|Prexxartan® (oral solution)
Diovan
EXFORGE
Kalpress
Miten
N-(p-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Nisis
|
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
PREXXARTAN
Provas
Tareg
VAL489
Vals
VALSARTAN
|
|
6 |
|
Angiotensin II |
Approved, Investigational |
Phase 4 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
7 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
8 |
|
DL-alpha-Tocopherol |
Approved, Experimental, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
59-02-9, 10191-41-0 |
2116 14985 |
Synonyms:
(-)-a-Tocopherol
(-)-Α-tocopherol
(+)-2R,4’R,8’R-α-Tocopherol
(+)-2R,4'R,8'R-alpha-Tocopherol
(+)-2R,4'R,8'R-α-Tocopherol
(+)-alpha-Tocopherol
(+)-a-Tocopherol
(+)-α-Tocopherol
(±)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4’R,8’R)-α-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'r,8'r)-a-Tocopherol
(2R,4'R,8'R)-α-Tocopherol
(all-R)-alpha-Tocopherol
(all-R)-α-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-α-Tocopherol
3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-(2R)-2H-1-benzopyran-6-ol
5,7,8-Trimethyltocol
a-D-Tocopherol
all-rac-alpha-tocopherol
Almefrol
ALPHA TOCOPHEROL
alpha-delta-Tocopherol
alpha-D-Tocopherol
alpha-Tocopherol
alpha-Vitamin E
Amino-Opti-E
AQUASOL E
a-Tocopherol
d-alpha-Tocopherol
Daltose
|
D-a-Tocopherol
delta-alpha-Tocopherol
Denamone
DL-5,7,8-trimethyltocol
DL-alpha tocopherol
DL-α-tocopherol
d-α-Tocopherol
E-200 I.U. Softgels
E307
E-Complex-600
E-Ferol
Emipherol
Eprolin
Etamican
E-VIMIN
E-Vitamin succinate
Evitaminum
Gordo-Vite E
NATOPHEROL
Phytogermin
Phytogermine
Profecundin
RRR-alpha-Tocopherol
RRR-alpha-Tocopheryl
TOCOPHEROL
Vitamin e
Vitamin E DL-alpha
Vitamin ea
Vitamin Ealpha
Vitamin Eα
Vitamin Plus E Softgells
Vitec
α-D-Tocopherol
α-Tocopherol
α-Vitamin E
|
|
9 |
|
Tocotrienol |
Investigational |
Phase 4 |
|
6829-55-6 |
9929901 |
Synonyms:
|
10 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
11 |
|
abobotulinumtoxinA |
|
Phase 4 |
|
|
|
Synonyms:
ABOBOTULINUMTOXINA
BONT/A
BONTOXILYSIN A
BOTOX
BOTULINUM TOXIN TYPE A
|
BOTULINUM TOXINS, TYPE A
BOTULOTOXIN A
BTX-A
ONABOTULINUMTOXINA
|
|
12 |
|
Botulinum Toxins, Type A |
|
Phase 4 |
|
|
|
13 |
|
Botulinum Toxins |
|
Phase 4 |
|
|
|
14 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
15 |
|
Retinol palmitate |
|
Phase 4 |
|
|
|
16 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
17 |
|
Vitamins |
|
Phase 4 |
|
|
|
18 |
|
Tocotrienols |
|
Phase 4 |
|
|
|
19 |
|
Tocopherols |
|
Phase 4 |
|
|
|
20 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
21 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
22 |
|
Estrogens |
|
Phase 4 |
|
|
|
23 |
|
Estrogen Receptor Antagonists |
|
Phase 4 |
|
|
|
24 |
|
Estrogen Antagonists |
|
Phase 4 |
|
|
|
25 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
26 |
|
Estrogen Receptor Modulators |
|
Phase 4 |
|
|
|
27 |
|
Selective Estrogen Receptor Modulators |
|
Phase 4 |
|
|
|
28 |
|
Evening Primrose |
|
Phase 4 |
|
|
|
29 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
30 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
31 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
32 |
|
Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate |
|
Phase 4 |
|
|
|
33 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
34 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
35 |
|
Angiotensinogen |
|
Phase 4 |
|
|
16133225 |
Synonyms:
Hypertensinogen
Proangiotensin
Renin substrate
Renin substrate tetradecapeptide
|
Renin-substrate
Serpin a8
SERPINA8
Tetradecapeptide, renin substrate
|
|
36 |
|
Angiotensin Receptor Antagonists |
|
Phase 4 |
|
|
|
37 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 4 |
|
|
|
38 |
|
Giapreza |
|
Phase 4 |
|
|
|
39 |
|
Sacubitril and valsartan sodium hydrate drug combination |
|
Phase 4 |
|
|
|
40 |
|
Evening primrose oil |
Investigational, Nutraceutical |
Phase 4 |
|
308064-97-3 |
|
Synonyms:
Oenothera biennis (evening primrose) oil
Oenothera biennis (evening primrose) seed extract
Oenothera biennis l. oil
Oenothera biennis seed extract
Oenothera biennis seed oil
Oenothera lamarckiana l. oil
Oenothera muricata seed oil
|
Oenothera oil
Oenothera pycnocarpa seed oil
Oenotherae biennis oleum
Oils, glyceridic, evening primrose
Oleum oenotherae erythrospinae
Primrose oil
|
|
41 |
|
Epirubicin |
Approved |
Phase 2, Phase 3 |
|
56420-45-2 |
41867 |
Synonyms:
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4'-Epi-DXR
Cell pharm brand OF epirubicin
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epilem
Epirubicin
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
|
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicina
Farmorubicine
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
|
|
42 |
|
Goserelin |
Approved |
Phase 2, Phase 3 |
|
65807-02-5 |
5311128 47725 |
Synonyms:
(2S)-1-[(2S)-2-{[(2S)-2-{[(2R)-3-(tert-butoxy)-2-{[(2S)-2-{[(2S)-1,3-dihydroxy-2-{[(2S)-1-hydroxy-2-{[(2S)-1-hydroxy-2-({hydroxy[(2S)-5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl]methylidene}amino)-3-(1H-imidazol-5-yl)propylidene]amino}-3-(1H-indol-3-yl)propylidene]amino}propylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxypropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-5-carbamimidamidopentanoyl]-N-[(C-hydroxycarbonimidoyl)amino]pyrrolidine-2-carboximidate
Acetate, goserelin
DECAPEPTIDE I
decapeptide I|ICI 118630|Zoladex®
Goserelin
Goserelin acetate
Goserelina
|
ICI 118
ICI 118630
ICI-118630
ICI-118630Zoladex
ZD9393
Zoladex
|
|
43 |
|
Ibuprofen |
Approved |
Phase 3 |
|
15687-27-1 |
3672 |
Synonyms:
(+-)-2-(p-Isobutylphenyl)propionate
(+-)-2-(p-Isobutylphenyl)propionic acid
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetate
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
(+-)-a-Methyl-4-(2-methylpropyl)benzeneacetate
(+-)-a-Methyl-4-(2-methylpropyl)benzeneacetic acid
(+-)-Ibuprofen
(+-)-p-Isobutylhydratropate
(+-)-p-Isobutylhydratropic acid
(+-)-Α-methyl-4-(2-methylpropyl)benzeneacetate
(+-)-Α-methyl-4-(2-methylpropyl)benzeneacetic acid
(±)-2-(P-ISOBUTYLPHENYL)PROPIONIC ACID
(±)-IBUPROFEN
(±)-P-ISOBUTYLHYDRATROPIC ACID
(±)-Α-METHYL-4-(2-METHYLPROPYL)BENZENEACETIC ACID
(4-Isobutylphenyl)-alpha-methylacetate
(4-Isobutylphenyl)-alpha-methylacetic acid
(4-Isobutylphenyl)-a-methylacetate
(4-Isobutylphenyl)-a-methylacetic acid
(4-Isobutylphenyl)-α-methylacetate
(4-Isobutylphenyl)-α-methylacetic acid
(RS)-Ibuprofen
2-(4-Isobutylphenyl)propanoate
2-(4-Isobutylphenyl)propanoic acid
4-Isobutylhydratropate
4-Isobutylhydratropic acid
a-(4-Isobutylphenyl)propionate
a-(4-Isobutylphenyl)propionic acid
a-(p-Isobutylphenyl)propionate
a-(p-Isobutylphenyl)propionic acid
ACHES-N-PAIN
Actiprofen
Adran
Advil
ADVIL LIQUI-GELS
ADVIL MIGRAINE LIQUI-GELS
Advil®|Brufen®|ibuprofen lysine|ibuprofen sodium|Motrin®|Nurofen®|U-18573
alpha-(4-Isobutylphenyl)propionate
alpha-(4-Isobutylphenyl)propionic acid
alpha-(p-Isobutylphenyl)propionate
alpha-(p-Isobutylphenyl)propionic acid
alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
alpha-p-Isobutylphenylpropionate
alpha-p-Isobutylphenylpropionic acid
Aluminum salt ibuprofen
Amersol
Amibufen
ANADIN JOINT PAIN
ANADIN LIQUIFAST
ANADIN PERIOD PAIN RELIEF
ANADIN ULTRA
Anco
Andran
Anflagen
Apo-Ibuprofen
Apsifen
APSIFEN-F
ARTHROFEN 200
ARTHROFEN 400
ARTHROFEN 600
Artril 300
Bluton
Brufanic
Brufen
BRUFEN RET
Brufort
Buburone
Butylenin
Calcium salt ibuprofen
CALDOLOR
CAP-PROFEN
CHILDREN'S ADVIL
CHILDREN'S ADVIL-FLAVORED
CHILDREN'S ELIXSURE
CHILDREN'S IBUPROFEN
CHILDREN'S MOTRIN
CODAFEN CONTINUS
Codral
CO-OP
CUPROFEN FOR CHILD
CUPROFEN PLUS
DEEP RELIEF
Dolgin
Dolgirid
Dolgit
Dolocyl
Dolo-dolgit
Duralbuprofen
Ebufac
Emodin
Epobron
Femadon
FEMAFEN
FENBID
FENBID FTE
Fenbid Spansule
FENPAED
FEVERFEN
FLEXIMEX
Haltran
I.V. solution, ibuprofen
IB-100
Ibu
Ibu-attritin
IBUCALM
IBUDERM
IBUFAC
Ibufen
IBUGEL
IBUGEL FTE
IBULAR
IBULEVE
IBUMED
Ibumetin
IBUMOUSSE
IBUPRIN
Ibuprocin
IBUPROFEN
Ibuprofen i.v. solution
Ibuprofen zinc
|
Ibuprofen, (+-)-isomer
Ibuprofen, (R)-isomer
Ibuprofen, (S)-isomer
Ibuprofen, aluminum salt
Ibuprofen, calcium salt
Ibuprofen, copper (2+) salt
Ibuprofen, magnesium salt
Ibuprofen, potassium salt
Ibuprofen, sodium salt
Ibuprofen, zinc salt
Ibuprofene
Ibuprofeno
Ibuprofenum
Ibuprofen-zinc
IBUPROHM
IBUPROPHEN
IBU-SLO
IBUSPRAY
IBU-TAB
IBU-TAB 200
Ibutid
IBUTIME
Ifen
Inabrin
Inoven
IP 82
IP-82
ISISFEN
JUNIFEN
JUNIOR STRENGTH ADVIL
JUNIOR STRENGTH IBUPROFEN
JUNIOR STRENGTH MOTRIN
Lamidon
Lebrufen
LIDIFEN
LIDIFEN-F
Liptan
LOBUFEN
M01AE01
Magnesium salt ibuprofen
MANDAFEN
MANORFEN
MAXA-GESIC
Medipren
MIDOL
Midol 200
MIDOL LIQUID GELS
MIGRAFEN
Motrin
MOTRIN IB
MOTRIN MIGRAINE PAIN
Mynosedin
Napacetin
NeoProfen
Nobfelon
Nobfen
Nobgen
NOVAPRIN
Novogent N
Novoprofen
NSC-256857
Nuprin
Nurofen
NUROFEN 400
NUROFEN BACK PAIN SR
NUROFEN CHILD
NUROFEN FOR CHILD
NUROFEN PLUS
NUROFEN RECOVERY
NUROFEN SINUS
NUROFEN SOLB
ORBIFEN
PACIFENE
Pantrop
Para-Isobutylhydratropic Acid
PAXOFEN
PEDEA
Pediaprofen
Pedia-Profen
PEDIATRIC ADVIL
PHENSIC
PHOR PAIN
PHORPAIN
PHORPAIN MAX STRGH
p-Isobutyl-2-phenylpropionate
p-Isobutyl-2-phenylpropionic acid
p-Isobutylhydratropate
p-Isobutylhydratropic acid
Potassium salt ibuprofen
PROFEN
PROFLEX
PROFLEX SR
Rafen
RD 13621
Rebugen
RELCOFEN
RIMAFEN
Roidenin
Rufen
Salprofen
Salt ibuprofen, magnesium
Salt ibuprofen, sodium
Salt ibuprofen, zinc
Seclodin
Sodium salt ibuprofen
Suspren
Tabalon
TAB-PROFEN
Trauma dolgit gel
Trauma-dolgit gel
TraumaDolgit gel
Trendar
U-18573
Urem
Zinc salt ibuprofen
Α-(4-isobutylphenyl)propionate
Α-(4-isobutylphenyl)propionic acid
Α-(p-isobutylphenyl)propionate
Α-(p-isobutylphenyl)propionic acid
|
|
44 |
|
Lidocaine |
Approved, Vet_approved |
Phase 3 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
45 |
|
Ketamine |
Approved, Vet_approved |
Phase 3 |
|
6740-88-1, 1867-66-9 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
Calipsol
Calypsol
CI 581 base
CLSTA 20
DL-Ketamine
Esketamine
Kalipsol
Ketaject
Ketalar
|
Ketalar base
Ketalar|ketamine HCl
Ketamina
KETAMINE
Kétamine
Ketamine base
Ketamine HCL
Ketamine hydrochloride
Ketaminum
Ketanest
Ketaset
Ketolar
L-Ketamine
NMDA
NSC-70151
Special K
Tekam
|
|
46 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
47 |
|
Remifentanil |
Approved |
Phase 3 |
|
132875-61-7 |
60815 |
Synonyms:
3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
GI 87084X
GI-87084B
IDS-NR-005
Remifentanil
|
Remifentanil hydrochloride
Remifentanil monohydrochloride
Remifentanilo
Remifentanyl
Ultiva
|
|
48 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
49 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 3 |
|
2078-54-8 |
4943 |
Synonyms:
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
2,6-diisopropylphenol|Diprivan®|ICI 35868
Abbott brand OF propofol
Alpha Brand OF propofol
Aquafol
Astra brand OF propofol
AstraZeneca brand OF propofol
Braun brand OF propofol
Curamed brand OF propofol
Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Fresenius brand OF propofol
Fresenius kabi brand OF propofol
Fresofol
ICI 35868
ICI 35-868
|
ICI35,868
ICI-35868
Ivofol
Juste brand OF propofol
NSC-5105
Parnell brand OF propofol
Pisa brand OF propofol
Propofol
Propofol abbott
Propofol fresenius
Propofol MCT
Propofol rovi
Propofol-lipuro
Propofolum
Rapinovet
Recofol
Rovi brand OF propofol
Schering brand OF propofol
Zeneca brand OF propofol
|
|
50 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
Interventional clinical trials:
(show top 50)
(show all 125)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial |
Unknown status |
NCT01427400 |
Phase 4 |
Botulinum Toxin-A;Saline |
2 |
A Multicenter, Randomized, Open, Parallel Controlled Clinical Study on the Efficacy and Safety of the Treatment of Cyclomastopathy With Xiaoru Sanjie Capsule |
Unknown status |
NCT02929420 |
Phase 4 |
Xiaoru Sanjie capsules;Xiao Yao pills |
3 |
Omega-3 Fatty Acids Plus Vitamin E Cosupplementation Versus Vitamin E in Fibrocystic Breast Patient |
Unknown status |
NCT04694027 |
Phase 4 |
Omega 3 fatty acid;VitaE |
4 |
Single-shot Pectoral Plane (PECs) Blocks Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECs Block and Local Anaesthetic Infusion After Non-ambulatory Breast Cancer Surgery: A Prospective, Randomised, Double-blind Trial |
Completed |
NCT03024697 |
Phase 4 |
|
5 |
A Single Blinded Randomized Controlled Trial of the Comparative Effects of Tamoxifen and Evening Primrose Oil in Premenopausal Non-high Risk Patients With Benign Breast Disease With Respect to the Estrogen Receptor Status. |
Completed |
NCT00999921 |
Phase 4 |
Tamoxifen;Evening Primrose Oil |
6 |
Contrast Enhanced Breast MRI: Comparison of Two Macrocyclic Gadolinium-Based Contrast Agents: Gadoterate Meglumine (Dotarem) and Gadobutrol (Gadavist). A Prospective Study. |
Recruiting |
NCT03730051 |
Phase 4 |
Gadoterate meglumine;Gadobutrol |
7 |
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent |
Not yet recruiting |
NCT05465031 |
Phase 4 |
Sacubitril-valsartan |
8 |
A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer |
Unknown status |
NCT01917279 |
Phase 3 |
Docetaxel plus Capecitabine;Intermittent Capecitabine;Metronomic Capecitabine |
9 |
Prospective Randomized Controlled Study on the Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer |
Unknown status |
NCT03373708 |
Phase 2, Phase 3 |
Epirubicin;Cyclophosphamide;Docetaxel;Goserelin acetate;Tamoxifen;Letrozole |
10 |
Randomized Controlled Trials of Diet and Lifestyle Intervention to Promote Chinese Postpartum Women's Health |
Unknown status |
NCT01039051 |
Phase 2, Phase 3 |
|
11 |
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGenâ„¢ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease |
Unknown status |
NCT00237523 |
Phase 3 |
IoGen (molecular iodine) |
12 |
A Multicenter, Randomized, Open-label, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. Versus Charcotrace Inj. in Patients With Nonpalpable Breast Lesions |
Completed |
NCT04606329 |
Phase 3 |
LuminoMark inj.(Conc. for fluorescence);Charcotrace Inj. |
13 |
Monitored Anesthesia Care Using Remifentanil and Ketofol Results in a Superior Quality of Recovery Compared With Total Intravenous Anesthesia in Ambulatory Breast Augmentation |
Completed |
NCT03764267 |
Phase 3 |
Remifentanil;general anesthetic |
14 |
Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial |
Completed |
NCT01591746 |
Phase 3 |
Botulinum Toxin Type A;Placebo |
15 |
A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3® for the Treatment of Pain After Breast Surgery. |
Completed |
NCT00299039 |
Phase 3 |
acetaminophen plus codeine;acetaminophen plus ibuprofen |
16 |
BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer |
Completed |
NCT00039780 |
Phase 3 |
BNP7787;Placebo |
17 |
Electronic Patient Reported Outcome Measures (ePROMs) in Patients With Breast Disease: An Open-label, Randomized Controlled Trial on Patient Reported Experience Measures (PREMs) and Effectivity (PREMs_PROMs) |
Completed |
NCT04718324 |
Phase 3 |
|
18 |
Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease |
Completed |
NCT00967681 |
Phase 3 |
|
19 |
BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation |
Recruiting |
NCT04711109 |
Phase 3 |
Denosumab;Placebo |
20 |
A Randomized, Controlled, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Breast Cancer and Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Advanced Breast With Liver Metastases |
Recruiting |
NCT03500380 |
Phase 2, Phase 3 |
RC48-ADC;Lapatinib;Capecitabine |
21 |
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System |
Unknown status |
NCT02511301 |
Phase 1, Phase 2 |
|
22 |
A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast |
Unknown status |
NCT00036998 |
Phase 2 |
|
23 |
A Multicenter, Open-label, Parallel, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. (Conc. for Fluorescence) Localization in Patients With Nonpalpable Breast Lesions |
Completed |
NCT03743259 |
Phase 2 |
LuminoMark inj. 0.1mL;LuminoMark inj. 0.2mL;Charcotrace Inj. |
24 |
A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer |
Completed |
NCT00050427 |
Phase 2 |
ET743 |
25 |
Guaraná ("Paullinia Cupana") for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study |
Completed |
NCT01043913 |
Phase 2 |
Guarana extract |
26 |
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease |
Completed |
NCT00744276 |
Phase 2 |
danazol;Placebo |
27 |
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease |
Completed |
NCT01849250 |
Phase 2 |
Docosahexaenoic Acid |
28 |
Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer |
Completed |
NCT01472146 |
Phase 2 |
Zo-Nantax |
29 |
A Single-arm, Multi-center Phase II Clinical Study of Pyrotinib Combined With Vinorelbine in the Treatment of HER2-positive and Treated Metastatic Breast Cancer |
Recruiting |
NCT04605575 |
Phase 2 |
Pyrotinib 320mg + Vinorelbine;Pyrotinib 400mg + Vinorelbine;Pyrotinib plus Vinorelbine |
30 |
A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancers |
Recruiting |
NCT03709446 |
Phase 1, Phase 2 |
Leflunomide |
31 |
An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer |
Recruiting |
NCT05386108 |
Phase 1, Phase 2 |
Abemaciclib;Elacestrant |
32 |
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions |
Recruiting |
NCT02928978 |
Phase 2 |
Ruxolitinib;Placebo (for Ruxolitinib) |
33 |
Targeted Prevention of Postpartum-Related Breast Cancer |
Recruiting |
NCT05557877 |
Phase 2 |
Low-Dose Aspirin |
34 |
Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) |
Recruiting |
NCT03979508 |
Phase 2 |
Abemaciclib |
35 |
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer |
Active, not recruiting |
NCT03304080 |
Phase 1, Phase 2 |
Anastrozole;Palbociclib;Trastuzumab;Pertuzumab |
36 |
Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the First-line Treatment of Advanced HER2-positive/HR-positive Breast Cancer Phase II Study |
Not yet recruiting |
NCT04088110 |
Phase 2 |
Pyrotinib;Trastuzumab;Aromatase Inhibitors |
37 |
A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer |
Not yet recruiting |
NCT03910712 |
Phase 2 |
Pyrotinib;Trastuzumab;Aromatase inhibitor |
38 |
GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer |
Terminated |
NCT01499160 |
Phase 2 |
letrozole;lapatinib;everolimus |
39 |
A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors |
Completed |
NCT02897778 |
Phase 1 |
Entinostat;Placebo |
40 |
A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) |
Completed |
NCT02909452 |
Phase 1 |
Entinostat;Pembrolizumab |
41 |
Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas |
Completed |
NCT00028496 |
Phase 1 |
|
42 |
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer: a Single-arm, Ahead, Open-label Study |
Unknown status |
NCT03756064 |
|
Pyrotinib;Trastuzumab;Docetaxel;Carboplatin;Placebo Oral Tablet |
43 |
Prospective, Multi-centre, Observational Trial Evaluating Outcomes of Immediate Breast Reconstruction Using an Implant and Acellular Dermal Matrix (SurgiMend) or Autologous Tissue |
Unknown status |
NCT02557906 |
|
|
44 |
A Randomized Study Evaluating the Safety and Effects of the Combination of Palbociclib With Epirubicin and Cyclophosphamide Followed by Paclitaxel as Neoadjuvant Therapy in Triple Negative Breast Cancer |
Unknown status |
NCT03756090 |
|
Palbociclib;Placebo oral capsule;Epirubicin;Cyclophosphamide;Paclitaxel |
45 |
A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery |
Unknown status |
NCT01654432 |
|
|
46 |
Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer |
Unknown status |
NCT01140763 |
|
|
47 |
Clinical Application of Breast Blood-oxygen Functional Imaging Technology |
Unknown status |
NCT01678170 |
|
|
48 |
Expedited Discharge of Patients Undergoing Pedicled TRAM Flap Breast Reconstruction Procedure in Ambulatory Surgical Facility: Quality of Recovery Outcomes |
Unknown status |
NCT01438268 |
|
|
49 |
Development of an Artificial Intelligence Precise Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics |
Unknown status |
NCT04535466 |
|
|
50 |
Risk Factors for Benign Breast Disease in Young Adult Women. Case-control Study |
Unknown status |
NCT04127422 |
|
|
Cochrane evidence based reviews: breast diseases
|